http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-052138-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
filingDate 2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2007-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-052138-A1
titleOfInvention PHARMACEUTICAL COMPOSITION OF SLOW RELEASE THAT INCLUDES (+) - (2S, 3S) -2- (3-CHLOROPHENYL) -3,5,5-TRIMETHYL-2-MORPHOLINOL AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
abstract Slow-release pharmaceutical composition comprising the compound of (+) - (2S, 3S) -2- (3-chlorophenyl) -3,5,5-trimethyl-2- morpholinol, of formula (1) or its salt or solvate Pharmaceutically acceptable, the composition is in tablet form and comprises speed controlling polymers, fillers and stabilizers. It can be administered orally and with a single daily dose. Use of the composition for the preparation of a medicament for the treatment of a disorder or a condition in a human subject, selected from depression, pain, chronic fatigue, obesity, anxiety disorders and mixed depression and anxiety disorder.
priorityDate 2004-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9795056

Total number of triples: 32.